Listed

Pfizer Inc: Form 10-Q for the period ended Jul 4, 2021

Filed with the SEC on Aug 12, 2021 and accepted by EDGAR at Aug 12, 2021, 16:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-07-04. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-04-05 to 2021-07-04$18.98bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2021-01-01 to 2021-07-04$33.56bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-04-05 to 2021-07-04$7.05bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2021-01-01 to 2021-07-04$11.26bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2021-04-05 to 2021-07-04$2.93bnus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2021-01-01 to 2021-07-04$5.71bnus-gaap:SellingGeneralAndAdministrativeExpense
Interest expense3 months2021-04-05 to 2021-07-04$316.0mus-gaap:InterestExpense
Interest expense6 months2021-01-01 to 2021-07-04$651.0mus-gaap:InterestExpense
Income tax3 months2021-04-05 to 2021-07-04$1.04bnus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2021-01-01 to 2021-07-04$1.85bnus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-04-05 to 2021-07-04$5.56bnus-gaap:NetIncomeLoss
Net income6 months2021-01-01 to 2021-07-04$10.44bnus-gaap:NetIncomeLoss
Diluted EPS3 months2021-04-05 to 2021-07-04$0.98us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2021-01-01 to 2021-07-04$1.84us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-04-05 to 2021-07-04$0.99us-gaap:EarningsPerShareBasic
Basic EPS6 months2021-01-01 to 2021-07-04$1.87us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-04-05 to 2021-07-045,678,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2021-01-01 to 2021-07-045,670,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2021-01-01 to 2021-07-04$15.84bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2021-01-01 to 2021-07-04$1.09bnus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-07-04$2.37bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-07-04$48.81bnus-gaap:AssetsCurrent
Total assetsAt period end2021-07-04$169.92bnus-gaap:Assets
Current liabilitiesAt period end2021-07-04$35.66bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-07-04$99.61bnus-gaap:Liabilities
Long-term debtAt period end2021-07-04$35.35bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2021-07-04$3.69bnus-gaap:LongTermDebtCurrent
Short-term borrowingsAt period end2021-07-04$100.0mus-gaap:CommercialPaper
Shareholders' equityAt period end2021-07-04$70.04bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000078003-21-000093. Last ingested by Listed: Nov 12, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.